Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05304936 · ClinicalTrials.gov registry record · Phase 1
HCW9218 for Advanced Pancreatic Cancer
A Phase 1 study, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05304936 is a Phase 1 study that has completed, run by ImmunityBio. The registered enrollment target is 21 participants.
The verdict
NCT05304936, a Phase 1 study, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic cancer.
Interventions
- DRUG Nab-paclitaxel
- DRUG HCW9218
- DRUG Gemcitabine (GEM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-10-17 |
| Est. Completion | 2025-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05304936
The ClinicalTrials.gov registry entry for NCT05304936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nab-paclitaxel is the first listed.
NCT05304936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05304936 about?
NCT05304936 is a clinical study titled "HCW9218 for Advanced Pancreatic Cancer". This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic cancer.
What is the current status of trial NCT05304936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-10-17. Estimated completion is 2025-02-15.
What interventions are being tested in trial NCT05304936?
The interventions under investigation include: Nab-paclitaxel (DRUG), HCW9218 (DRUG), Gemcitabine (GEM) (DRUG).
Who is sponsoring clinical trial NCT05304936?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.